Evidence map›Paper›PMID 27002369›Full record

ReviewHuman vaccines & immunotherapeutics2016

Current status of new tuberculosis vaccine in children.

Yu Pang, Aihua Zhao, Chad Cohen, Wanli Kang, Jie Lu, Guozhi Wang, Yanlin Zhao, Suhua Zheng

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. An Update on Tuberculosis Vaccines.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  8. Review
  9. Article
  10. Molecules (Basel, Switzerland) · 2020
    Review
  11. Review
  12. Article
  13. Current trends in tuberculosis vaccine.Medical journal, Armed Forces India · 2019
    Review
  14. Article
  15. Expression and purification of Rv2654 recombinant protein fromZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Yu Panga Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University , Beijing , China.
Aihua Zhaoc National Institute for Food and Drug Control , Beijing , China.
Chad Cohend McGill International TB Centre, Montreal , Quebec , Canada.
Wanli Kanga Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University , Beijing , China.
Jie Lue Beijing Key Laboratory for Pediatric Diseases of Otolaryngology, Head and Neck Surgery, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University , Beijing , China.
Guozhi Wangc National Institute for Food and Drug Control , Beijing , China.
Yanlin Zhaob National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention , Beijing , China.
Suhua Zhenga Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University , Beijing , China.
Capital Medical University · CNChinese Center For Disease Control and Prevention · CNNational Institutes for Food and Drug Control · CNBeijing Chest Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pediatric tuberculosis contributes significantly to the burden of TB disease worldwide. In order to achieve the goal of eliminating TB by 2050, an effective TB vaccine is urgently needed to prevent TB transmission in children. BCG vaccination can protect children from the severe types of TB such as TB meningitis and miliary TB, while its efficacy against pediatric pulmonary TB ranged from no protection to very high protection. In recent decades, multiple new vaccine candidates have been developed, and shown encouraging safety and immunogenicity in the preclinical experiments. However, the limited data on protective efficacy in infants evaluated by clinical trials has been disappointing, an example being MVA85A. To date, no vaccine has been shown to be clinically safer and more effective than the presently licensed BCG vaccine. Hence, before a new vaccine is developed with more promising efficacy, we must reconsider how to better use the current BCG vaccine to maximize its effectiveness in children.

Indexed as

BCG VaccineTuberculosis VaccinesChildClinical Trials as TopicHumansMycobacterium tuberculosisTuberculosisTuberculosis, PulmonaryVaccinationVaccines, DNABCG VaccineMVA 85ATuberculosis VaccinesVaccines, DNABCGchildrenimmune responsetuberculosisvaccination

Identifiers

PMID27002369
PMCPMC4962963
OpenAlexW2308163573

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.